Biopartners terminates collaboration with The Medical House

Baar, Switzerland 17 December 2007: Biopartners Holdings AG today announced that it has terminated its supply agreement with The Medical House. In February 2005, The Medical House signed a 10 year supply agreement with Biopartners GmbH for the license and supply of The Medical House’s GH1 reusable, spring powered, needle-free delivery system for the delivery of Biopartners’ human growth hormone product, Valtropin®.

In 2006 Biopartners initiated a comparative bioavailability/bioequivalence study in volunteers to assess Valtropin delivered by The Medical House’s GH1. The Medical House has never been able to supply Biopartners with the GH1 devices needed to perform this clinical study. Therefore, Biopartners terminated the collaboration.

“Having received EMEA approval in April 2006, we had planned to launch Valtropin at the end of that year” commented Mr Jean-Noël Treilles, CEO of Biopartners. “However, with the

GH1 device not functioning correctly, we have had to end our agreement with The Medical House in order to seek a suitable and robust alternative delivery system.”